Trading Report: Today, Intercept Pharmaceuticals Inc. (ICPT) Earns Outperform Rating from Wedbush

Today, Intercept Pharmaceuticals Inc. (ICPT) Earns Outperform Rating from Wedbush

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a report released on Saturday. They currently have a $224.00 price target on the biopharmaceutical company’s stock. Wedbush’s price target would indicate a potential upside of 93.37% from the stock’s previous close.

ICPT has been the topic of a number of other reports. Zacks Investment Research lowered shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 2nd. Wells Fargo & Co. reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 28th. Leerink Swann reaffirmed a “positive” rating and issued a $159.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, October 14th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $200.00 price target (down from $250.00) on shares of Intercept Pharmaceuticals in a report on Monday, October 24th. Finally, FBR & Co reaffirmed a “neutral” rating on shares of Intercept Pharmaceuticals in a report on Friday, November 18th. Five analysts have rated the stock with a sell rating, four have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $177.07.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.37% on Friday, hitting $115.84. The stock had a trading volume of 207,545 shares. Intercept Pharmaceuticals has a 12 month low of $89.76 and a 12 month high of $186.87. The firm’s 50-day moving average price is $124.14 and its 200 day moving average price is $145.79. The firm’s market cap is $2.87 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.82) by $0.23. The firm had revenue of $4.70 million for the quarter, compared to analyst estimates of $4.77 million. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The business’s quarterly revenue was up 1051.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.10) earnings per share. Analysts anticipate that Intercept Pharmaceuticals will post ($15.63) EPS for the current fiscal year.

In other news, insider Lisa Bright sold 155 shares of the stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $163.20, for a total value of $25,296.00. Following the completion of the sale, the insider now owns 18,305 shares of the company’s stock, valued at approximately $2,987,376. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Mark Pruzanski sold 35,000 shares of the stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $165.00, for a total transaction of $5,775,000.00. Following the completion of the sale, the chief executive officer now directly owns 579,314 shares of the company’s stock, valued at approximately $95,586,810. The disclosure for this sale can be found here. 9.20% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Emerald Acquisition Ltd. purchased a new stake in Intercept Pharmaceuticals during the second quarter valued at $605,000. Societe Generale purchased a new stake in Intercept Pharmaceuticals during the second quarter valued at $1,697,000. Wedbush Securities Inc. boosted its stake in Intercept Pharmaceuticals by 1.8% in the second quarter. Wedbush Securities Inc. now owns 2,260 shares of the biopharmaceutical company’s stock valued at $322,000 after buying an additional 40 shares during the period. California State Teachers Retirement System boosted its stake in Intercept Pharmaceuticals by 2.4% in the second quarter. California State Teachers Retirement System now owns 34,759 shares of the biopharmaceutical company’s stock valued at $4,959,000 after buying an additional 823 shares during the period. Finally, Bbva Compass Bancshares Inc. boosted its stake in Intercept Pharmaceuticals by 5.4% in the second quarter. Bbva Compass Bancshares Inc. now owns 1,948 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 99 shares during the period. 81.54% of the stock is owned by institutional investors and hedge funds.

Intercept Pharmaceuticals Company Profile

Related posts

Leave a Comment